Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CLD-101 by Calidi Biotherapeutics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
CLD-101 is under clinical development by Calidi Biotherapeutics and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to...
CLD-101 by Calidi Biotherapeutics for High-Grade Glioma: Likelihood of Approval
CLD-101 is under clinical development by Calidi Biotherapeutics and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase...
CLD-101 by Calidi Biotherapeutics for Anaplastic Oligoastrocytoma: Likelihood of Approval
CLD-101 is under clinical development by Calidi Biotherapeutics and currently in Phase I for Anaplastic Oligoastrocytoma. According to GlobalData, Phase...
CLD-101 by Calidi Biotherapeutics for Oligodendroglioma: Likelihood of Approval
CLD-101 is under clinical development by Calidi Biotherapeutics and currently in Phase I for Oligodendroglioma. According to GlobalData, Phase I...
CLD-101 by Calidi Biotherapeutics for Gliosarcoma: Likelihood of Approval
CLD-101 is under clinical development by Calidi Biotherapeutics and currently in Phase I for Gliosarcoma. According to GlobalData, Phase I...
CLD-101 by Calidi Biotherapeutics for Anaplastic Astrocytoma: Likelihood of Approval
CLD-101 is under clinical development by Calidi Biotherapeutics and currently in Phase I for Anaplastic Astrocytoma. According to GlobalData, Phase...
CLD-101 by Calidi Biotherapeutics for Glioblastoma Multiforme (GBM): Likelihood of Approval
CLD-101 is under clinical development by Calidi Biotherapeutics and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...